How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. - Wikidata - wikimedia - TriplyDB

How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.

How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.

http://www.wikidata.org/entity/Q38476241

about

Transfusion as an Inflammation Hit: Knowns and Unknowns Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa.CD4 Depletion or CD40L Blockade Results in Antigen-Specific Tolerance in a Red Blood Cell Alloimmunization Model.A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease.Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.Anti-CD20 Antibody Prevents Red Blood Cell Alloimmunization in a Mouse Model.Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion.Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing.How I safely transfuse patients with sickle cell disease and manage delayed hemolytic transfusion reactions.Possible Risk Factors for Severe Anemia in Hospitalized Sickle Cell Patients at Muhimbili National Hospital, Tanzania: Protocol for a Cross-Sectional Study.

P2860

Q28074933-1F43BFD4-D9A7-4D70-B6F4-2B092C66D7F4 Q30243937-4ECC0F37-E993-404B-B032-7481A1388A60 Q38616688-5264384B-99F5-45FC-9029-08F65F9F0E9E Q38930968-4D8BBCD9-8D93-436C-B3BF-B39169B94DEB Q38949082-A4CEE4EF-68C5-4FDB-A86B-5A3B090BF008 Q47621588-EA00A97F-AE91-4786-9E36-FEE2EC384544 Q48326469-074DC516-4012-448B-BA1B-F624FB68E249 Q50437265-B030ADDC-6E43-486F-9397-B743E2D8D162 Q51678751-D866D7C4-38BB-40BA-A3B4-511489E5C89B Q52431898-A7245C7F-1FCC-46E1-B1FC-A955D0583D30 Q53686375-01E101B4-5D21-422A-B8BA-052CC65C31C9 Q53701676-4FF54518-9CD7-4F50-94B1-917606479B50

P2860

How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.

http://www.wikidata.org/entity/Q38476241

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

How we treat delayed haemolyti ...... ents with sickle cell disease.

@en

type

label

How we treat delayed haemolyti ...... ents with sickle cell disease.

@en

prefLabel

How we treat delayed haemolyti ...... ents with sickle cell disease.

@en

P1433

Q38476241-6F8E420D-9EE4-4169-B962-81555AA2D841

P1476

Q38476241-17221B57-B932-4CC5-BF57-19213FE50A47

P2093

Q38476241-29A6204F-B844-420E-8360-79D1AB61230A

Q38476241-483468F4-2300-4007-BE2B-D2A293584982

Q38476241-C743AA48-CA52-4D2A-8CA1-0D74BDB0565B

P2860

Q38476241-026946CC-FDC9-458C-8EB4-1EACC21B20BD

Q38476241-06098346-8B27-4ECF-ADEF-F8A14A92AD09

Q38476241-0FEC139C-B21C-4F55-A48B-5EA91918EBBD

Q38476241-10AFAC2F-09AC-46D1-BC9B-3C3CEF27C8F1

Q38476241-155D404B-5F1A-49B1-9094-18C7793CAD65

Q38476241-17C1ED08-451D-4E15-8E6F-56C812BD0763

Q38476241-194FC6F4-F083-4CF7-A846-5BEE6A87A6EC

Q38476241-2257D13E-2E82-4FCF-9BA6-42ACD35D7028

Q38476241-2ABD931E-F773-4027-BC67-EEBDE4E7B8A1

Q38476241-2BAF02C9-C2CF-4BC5-BCAB-F83EDA87D02A

P304

Q38476241-EF38BFB6-DB9B-4D67-8CAE-5D7A70172F69

P31

Q38476241-2A2040A9-B748-4577-BEF3-1366520CD9F9

P356

Q38476241-99926569-BE76-4D7D-8894-6D0ABB3E3B0A

P407

Q38476241-7F43E7D3-0699-4199-AD78-75C3130399A4

P433

Q38476241-E06BA58B-2583-424E-8AE5-ECD05A7C3C99

P478

Q38476241-9C79CA44-2FDA-4EBE-8102-2E6D69656948

P50

Q38476241-7AAB1177-2B7C-4242-BA09-88D1D3562589

P577

Q38476241-138AA4DC-8863-4E0C-B69E-FAB9541DA2C9

P5875

Q38476241-F0F1A47B-2CE4-484D-83F9-B6DFE2461E17

P698

Q38476241-885DC16A-B44D-48EC-AA86-B0F44E392057

P921

Q38476241-0E663BF8-D47E-4A6C-92C0-5D01E78D525B

P356

P1433

British Journal of Haematology

P1476

How we treat delayed haemolyti ...... ents with sickle cell disease.

@en

P2093

Aleksandar Mijovic

http://www.w3.org/2001/XMLSchema#string

Carolyn Hoppe

http://www.w3.org/2001/XMLSchema#string

Kate Gardner

http://www.w3.org/2001/XMLSchema#string

P2860

Multifocal osteosarcoma: an unusual presentation.

Delayed hemolytic transfusion reaction in sickle cell disease

Blood transfusion usage among adults with sickle cell disease - a single institution experience over ten years.

Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.

Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.

Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.

Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.

Severe neurologic complication after delayed hemolytic transfusion reaction in 2 children with sickle cell anemia: significant diagnosis and therapeutic challenges.

Delayed hemolytic transfusion reaction in children with sickle cell disease.

P304

745-756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13494

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276362873

http://www.w3.org/2001/XMLSchema#string

P698

25967919

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease